Clinically important, potentially hazardous interactions with: CYP1A2 and CYP2D6 substrates
Pregnancy: There are no available data with the use of givosiran in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.